We can evaluate your symptoms and determine the best course of action
Together they make Wegovy the first weight-loss medication with an FDA-approved CV-reduction indication
That would help patients with treatment-resistant insomnia, patients in structured opioid withdrawal programs, and potentially patients with narcolepsy who have not responded to standard medications
A summary of approximate phases, based on trial data, is as follows: Weeks 14: Appetite suppression and early metabolic changes may begin Weeks 412: Noticeable weight loss may commence Weeks 1248+: Progressive weight reduction, continuing through the trial period at higher doses These timelines reflect phase 2 trial experience and may differ in real-world settings
30 mg/mL concentration conversion table Ultra-concentrated formulations exist for people on the highest therapeutic doses who want minimal injection volumes
This can lower both total and free testosterone levels, reducing libido, energy, and muscle maintenance